Minimal residual disease in solid tumors: an overview.
10.1007/s11684-023-1018-6
- Author:
Yarui MA
1
;
Jingbo GAN
2
;
Yinlei BAI
2
;
Dandan CAO
2
;
Yuchen JIAO
3
Author Information
1. State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
2. Genetron Health (Beijing) Co. Ltd., Beijing, 102206, China.
3. State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. jiaoyuchen@126.com.
- Publication Type:Review
- Keywords:
CTC;
MRD;
ctDNA;
solid tumor
- From:
Frontiers of Medicine
2023;17(4):649-674
- CountryChina
- Language:English
-
Abstract:
Minimal residual disease (MRD) is termed as the small numbers of remnant tumor cells in a subset of patients with tumors. Liquid biopsy is increasingly used for the detection of MRD, illustrating the potential of MRD detection to provide more accurate management for cancer patients. As new techniques and algorithms have enhanced the performance of MRD detection, the approach is becoming more widely and routinely used to predict the prognosis and monitor the relapse of cancer patients. In fact, MRD detection has been shown to achieve better performance than imaging methods. On this basis, rigorous investigation of MRD detection as an integral method for guiding clinical treatment has made important advances. This review summarizes the development of MRD biomarkers, techniques, and strategies for the detection of cancer, and emphasizes the application of MRD detection in solid tumors, particularly for the guidance of clinical treatment.
